Tandem Capital Management’s Unicycive Therapeutics UNCY Stock Holding History

Tandem Capital Management’s Portfolio UNCY Stock Details UNCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,550	Closed	-$8.91K	–	119
2025 Q1	$8.91K	Hold	1,550	–	–	0.01%	113
2024 Q4	$12.3K	Hold	1,550	–	–	0.01%	112
2024 Q3	$6.32K	Hold	1,550	–	–	﹤0.01%	115
2024 Q2	$7.08K	Hold	1,550	–	–	﹤0.01%	112
2024 Q1	$21.4K	Hold	1,550	–	–	0.01%	109
2023 Q4	$13.4K	Hold	1,550	–	–	0.01%	111
2023 Q3	$13.3K	Hold	1,550	–	–	0.01%	107
2023 Q2	$19.8K	Hold	1,550	–	–	0.01%	107
2023 Q1	$32.5K	Hold	1,550	–	–	0.02%	105
2022 Q4	$8.37K	Hold	1,550	–	–	0.01%	96
2022 Q3	$10K	Hold	1,550	–	–	0.01%	91
2022 Q2	$13K	Hold	1,550	–	–	0.01%	91
2022 Q1	$17K	Hold	1,550	–	–	0.01%	93
2021 Q4	$32K	Hold	1,550	–	–	0.02%	92
2021 Q3	$44K	Buy	+1,550	New	+$44.5K	0.03%	87

Other funds holding UNCY

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tandem Capital Management's UNCY Position: Q2 2025 in Review

Tandem Capital Management sold out of Unicycive Therapeutics (UNCY) in Q2 2025, closing a stake of 1,550 shares — an estimated $8.91K sold.

Tandem Capital Management first reported a position in UNCY in Q3 2021 and held it in 15 quarters. The position peaked at $44K in Q3 2021. 20 funds tracked by Wall St. Rank hold UNCY as of Q2 2025.

Tandem Capital Management reported no remaining Unicycive Therapeutics position as of Q2 2025 after selling out during the quarter.
Tandem Capital Management sold 1,550 Unicycive Therapeutics shares in Q2 2025, an estimated $8.91K.
Tandem Capital Management first reported a position in Unicycive Therapeutics in Q3 2021 and held it in 15 quarters.
Tandem Capital Management's Unicycive Therapeutics position peaked at $44K in Q3 2021.
20 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2025.

Based on Tandem Capital Management's 13F filing for Q2 2025, filed 24 Jul 2025.